MAZE Stock Analysis: Buy, Sell, or Hold?
MAZE - Maze Therapeutics, Inc. Common Stock
$26.41
0.84 (3.29%)
▲
5d:
+8.82%
30d:
+2.56%
90d:
-46.1%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When MAZE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MAZE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MAZE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MAZE is currently trading at $26.41, which is considered extended relative to its 30-day fair value range of $24.07 to $25.93.
Technical Outlook: Technically, MAZE is in a strong downtrend. The price is approaching resistance at $26.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: MAZE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $62.55 (+136.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MAZE is in a strong downtrend. The price is approaching resistance at $26.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: MAZE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $62.55 (+136.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.07 -
$25.93
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 136.8% below Wall St target ($62.55)
Trading Range Analysis
30-Day Trading Range
$24.07 -
$25.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$22.71
Resistance Level
$26.32
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.99
Wall Street Target
$62.55
(+136.8%)
Share & Embed Analysis
Last updated: June 24, 2026 9:18 AM ET
Data refreshes hourly during market hours. Next update: 10:18 AM
Data refreshes hourly during market hours. Next update: 10:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MAZE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Harold Bernstein
SELL
15000 shares
2026-04-01
Amy Bachrodt
SELL
2500 shares
2026-04-01
Harold Bernstein
SELL
15000 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
